iconiifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Q4FY23 Review: JB Chemicals & Pharma: Higher GMs drive guidance upgrade for FY24

21 Mar 2024 , 05:46 PM

JB’s India Formulations business is expected to sustain its organic mid-teens growth trajectory over the next few years, driven by the scale-up in company’s Chronic portfolio led by its strong positioning in Cardiac segment, sustained volume growth of 7-8% in existing portfolio, and price hike contribution of 6-7%. CMO business will also benefit from new launches across product segments/markets, and is likely to grow low-double-digits to mid-teens in FY24. With GMs expected to improve from 63% in FY23 (64% in Q4) to 65% in FY24 driven by RM moderation and lower Azmarda sales, mgmt has upgraded its Ebitda margin guidance (ex-ESOP) by 100bps to 25-27% for FY24.

Organic India business expected to grow in mid-teens: JB’s organic India business grew 15% in FY23, and 20% Cagr over FY20-23 driven by volume growth of 8% and 5% contribution from new products. With 20- 24% sales Cagr in key brands of Cilacar, Rantac & Metrogyl over past 2 years, JB’s India PCPM has improved from Rs4.4 lakhs in FY21 to Rs6.2 lakhs in FY23, despite the impact of recent acquisitions. Analysts of IIFL Securities expect JB’s India business to grow at 15% Cagr over FY23-26, driven by 20% growth in Chronic portfolio (53% of India sales) and 8-10% growth in Acute portfolio.

Execution in acquired India portfolio has also been robust, with Azmarda & Sporlac growing 40-45% in FY23. While JB’s Azmarda volumes have increased 25% in Apr’23 vs pre-generic volumes, Azmarda’s monthly sales is sustaining at 75% of pre-generic levels with JB’s value MS being 15% currently. In-sourcing of Azmarda manufacturing will help JB to improve GM profile in FY24. Also, geographic expansion and prescriber overlap has aided JB to expand Sporlac’s MS from 7% to 10%.

CMO order book remains healthy and the segment is likely to grow in low-double-digits to mid-teens in FY24, on top of 60% growth seen in FY23. CMO lozenges business will benefit from new launches in Sleep disorders, Anti-inflammatory & Immunity segments in Q4FY24 and also from new market entries in South Africa (by Q2FY24) and later in India.

Analysts of IIFL Securities were already building-in 26% operating Ebitda margins and they largely maintain their estimate of 14/19% revenue/Ebitda Cagr over FY23-26. JB (TP Rs2,400) remains their preferred pick among Domestic Formulation companies, given its strong FCF generation of Rs6-8bn p.a. (FCF yield of 4.5%) over FY23-26 and RoIC (post-tax) expected to improve from 18% in FY23 to 25-30% in FY25/26.

Related Tags

  • JB Chemicals & Pharma
  • JB Chemicals & Pharma Q4
sidebar mobile

BLOGS AND PERSONAL FINANCE

Images
28 Mar 2024   |   03:36 PM
Images
28 Mar 2024   |   03:01 PM
Images
28 Mar 2024   |   01:21 PM
Images
28 Mar 2024   |   01:02 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.